Stryker Corporation · NYSE:SYK
Stryker — Merger or Acquisition (February 2016)
11 slides from Stryker's merger presentation, Feb 1, 2016
Slide 1: Stryker: Sage Products, LLC
Stryker Sage Products, LLC. February 1, 2016
Slide 2: Forward looking statement
Forward looking statement This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed
Slide 3: Strategic rationale
Strategic rationale • Provides access to a segment leading and fast growing portfolio of innovative products with a proven history of success • Brings a balanced and broad product offering with clinically and financially validated outcomes data • The combination accelerates Medical’s growth profile
Slide 4: Sage business summary
Sage business summary • Privately-held Sage develops, manufactures and distributes disposable products targeted at reducing “Never Events,” primarily in the ICU and MedSurg hospital unit setting • 45-year history of innovation with products that include solutions for oral care, skin preparation and
Slide 5: Sage product categories
Sage product categories 4 focused innovative product segments, each ~$100+ million in revenues, directly and cost-effectively reducing hospital acquired conditions and improving healthcare worker safety Oral Care Comfort Brand CHG Pre-Op Prep Prevalon #1 #1 #1 #1 Prevention of Prevention of skin
Slide 6: What makes Sage a unique healthcare platform
What makes Sage a unique healthcare platform 1 2 Uniquely valuable Sage’s market creating brand: the only products fill unmet needs, company exclusively holding #1 shares and focused on preventing creating a demonstrated 7 HACs value proposition 3 A management team Always innovating: and values-base
Slide 7: #1 Position in all markets served
#1 Position in all markets served Leading Market Positions with Superior Product Quality Premium products serving markets of approximately $1.8B in North America o Products recognized as superior in terms of ability to deliver positive patient outcomes, effectiveness and ease of use Consistent m
Slide 8: Cost of HACs addressed by Sage is significant
Cost of HACs addressed by Sage is significant Approximately $30B in annual US healthcare expenditures to treat hospital- acquired conditions; solutions portfolio aligned well with CMS mandates Ventilator-associated events (“VAEs”) most common infection in the ICU with each Ventilator-Associated ca
Slide 9: 45-year history of innovation
45-year history of innovation Demonstrated ability to History of Innovative consistently identify unmet Firsts needs, create new markets Product Launch Year and expand call points M-Care 2015 outside of ICU, including Prevalon Liftaem 2015 the OR, physical therapy Seated Positioning System 2013 and
Slide 10: Evidence-based solutions
Evidence-based solutions Each product line supported by clinical research highlighting improvement in outcomes associated with use of the company’s products “The new oral hygiene procedure tested in this study included components that address three risk factors: bacterial colonization of the orophar
Slide 11: Sage transaction
Sage transaction • All cash transaction for $2.775B, funded with both current cash and newly issued debt • The transaction includes an anticipated future tax benefit which is expected to exceed $500 million and to positively impact cash flows over approximately 15 years. • Sage has higher organic sa